Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 13/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140213 | 1.00 | EPHA2 (0.43) | EPHA2ERBB2EPHB4EGFRGPR119 | |
| SCHEMBL30140188 | 1.00 | EPHA2 (0.43) | EPHA2ERBB2EPHB4EGFRGPR119 | |
| SCHEMBL30140103 | 0.98 | EPHA2 (0.42) | EPHA2ERBB2EPHB4EGFRGPR119 | |
| SCHEMBL30140418 | 0.98 | EPHA2 (0.42) | EPHA2ERBB2EPHB4EGFRGPR119 | |
| SCHEMBL30140116 | 0.97 | EPHA2 (0.44) | EPHA2ERBB2EPHB4EGFRGPR119 | |
| SCHEMBL30140290 | 0.94 | GPR119 (0.43) | EPHA2ERBB2EPHB4EGFRGPR119 | |
| SCHEMBL30140158 | 0.94 | GPR119 (0.43) | EPHA2ERBB2EPHB4EGFRGPR119 | |
| SCHEMBL30140268 | 0.90 | EGFR (0.48) | ERBB2EGFRGPR119PIK3CDPIK3CA | |
| SCHEMBL30140135 | 0.90 | EGFR (0.47) | ERBB2EGFRGPR119PIK3CDPIK3CA | |
| SCHEMBL30140265 | 0.89 | EGFR (0.54) | ERBB2EPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266426-A1 | 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |